All In Biotech

Drug Trial Radar · NCT05456191

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 568 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

568

Actual

Start

Nov 21, 2022

Primary completion

May 15, 2025

Study completion Jul 7, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study was to assess the tolerability of oral asciminib (80 mg QD) in comparison with that of the second generation (2G) Tyrosine Kinase Inhibitor (TKI) nilotinib (300 mg BID), in adult patients with newly diagnosed Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).

Conditions

  • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Interventions

  • AsciminibDrug

    Asciminib 80 mg QD administered under fasting conditions.

  • NilotinibDrug

    Nilotinib 300 mg twice a day (BID) was administered under fasting conditions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis)Time frame: From date of first dose to date of treatment discontinuation due to AE, assessed after 50 events had occurred, about 2 years since first patient first visit (FPFV).
  2. Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Primary Analysis)Time frame: From date of first dose to date of treatment discontinuation due to AE, assessed after 67 events had occurred, about 2.5 years since first patient first visit (FPFV),

Locations

119 sites in 24 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Illinois Cancer Care

    Peoria, Illinois

  • Regions Hospital

    Saint Paul, Minnesota

  • Messino Cancer Centers

    Asheville, North Carolina

  • Oncology Hematology Care Inc

    Cincinnati, Ohio

  • Williamette Cancer Center

    Eugene, Oregon

  • Texas Oncology P A

    Bedford, Texas

  • Texas Oncology PA Bedford

    Bedford, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Plovdiv, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Varna, Bulgaria

  • Novartis Investigative Site

    London, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Plzen Bory, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Caen, France

  • Novartis Investigative Site

    Clermont-Ferrand, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Poitiers, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, France

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Augsburg, Germany

Showing 40 of 119 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.